首页> 外文期刊>Drug delivery. >Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib
【24h】

Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib

机译:脂质体,转移体和脂质体作为载体改善塞来昔布局部递送的比较研究

获取原文
       

摘要

Topical administration of celecoxib proved to be an effective mean of preventing skin cancer development and improving anticancer drugs effectiveness in skin tumors treatment. The aim of this study was the development of an effective topical formulation of celecoxib, able to promote drug skin delivery, providing its in depth penetration through the skin layers. Three kinds of vesicular formulations have been investigated as drug carriers: liposomes containing a surfactant, or transfersomes and ethosomes, containing suitable edge activators. Firstly, the effect of membrane composition variations on the system performance has been evaluated for each vesicle type. Selected formulations were characterized for particle size, polydispersity index and encapsulation efficiency. The best formulations were subjected to ex vivo permeation studies through excised human skin. All vesicular formulations markedly (p 0.001) improved the drug amount penetrated into the skin with respect to an aqueous suspension, from 2.0 to 6.5, up to 9.0 folds for liposomes, transfersomes and ethosomes, respectively. In particular, ethosomes containing Tween 20 as edge activator not only showed the best vesicle dimensions and homogeneity, and the highest encapsulation efficacy (54.4%), but also enabled the highest increase in drug penetration through the skin, probably due to the simultaneous presence in their composition of ethanol and Tween 20, both acting as permeation enhancers. Therefore, among the various vesicular formulations examined in the study, Tween 20-ethosomes can be considered the most promising one as carrier for topical celecoxib applications aimed to prevent skin cancer development and increase the anticancer drugs effectiveness against skin tumors.
机译:塞来昔布的局部给药被证明是预防皮肤癌发展和提高抗癌药在皮肤肿瘤治疗中有效性的有效手段。这项研究的目的是开发一种有效的塞来昔布局部制剂,该制剂能够促进药物向皮肤的递送,并使其深入皮肤层。已经研究了三种作为药物载体的囊泡制剂:含有表面活性剂的脂质体,或含有合适的边缘活化剂的转移体和脂质体。首先,已针对每种囊泡类型评估了膜组成变化对系统性能的影响。对选定的制剂进行粒度,多分散指数和包封效率的表征。最好的制剂通过切除的人皮肤进行离体渗透研究。相对于水性悬浮液,所有囊泡制剂均显着(p <0.001)改善了渗透到皮肤中的药物量,从2.0到6.5,对于脂质体,传递体和质体,分别提高了9.0倍。尤其是,含有吐温20作为边缘激活剂的核糖体不仅显示出最佳的囊泡尺寸和均质性,以及最高的包封功效(54.4%),而且还使得药物通过皮肤的渗透率增加最高,这可能是由于在体内同时存在它们的乙醇和吐温20的组成,都充当渗透促进剂。因此,在研究中研究的各种囊泡制剂中,吐温20核糖体被认为是最有前途的载体,可作为局部塞来昔布应用的载体,目的在于预防皮肤癌的发展并提高抗癌药对皮肤肿瘤的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号